Compare NUVB & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | OFIX |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 622.1M |
| IPO Year | N/A | N/A |
| Metric | NUVB | OFIX |
|---|---|---|
| Price | $6.47 | $14.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $10.44 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 5.9M | 206.7K |
| Earning Date | 11-03-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $26,748,000.00 | ★ $818,058,000.00 |
| Revenue This Year | $609.55 | $3.97 |
| Revenue Next Year | $197.91 | $5.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1137.19 | 4.31 |
| 52 Week Low | $1.54 | $10.24 |
| 52 Week High | $9.75 | $20.48 |
| Indicator | NUVB | OFIX |
|---|---|---|
| Relative Strength Index (RSI) | 30.88 | 41.49 |
| Support Level | $8.04 | $14.72 |
| Resistance Level | $9.10 | $16.42 |
| Average True Range (ATR) | 0.52 | 0.59 |
| MACD | -0.39 | -0.03 |
| Stochastic Oscillator | 11.03 | 5.59 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.